Ontada Research Symposium

From Data to Impact: How RWE is Shaping Strategy Across the Product Lifecycle

Wednesday, October 7, 2026 · Boston, MA · 8:00 AM – 3:30 PM EST

Ontada's Research Symposium brings together oncology leaders and innovators to discuss current trends, challenges and opportunities in leveraging real-world data and generating impactful real-world evidence.

We hope you can join us to hear how AI is changing real-world evidence generation, how biopharma companies are innovating in this space, and to network with colleagues and peers across the industry.

We will kick-off the event with a networking reception on October 6th at 6pm, followed by the Symposium the next day starting at 8am.

We are continually adding sessions to the agenda so check back to see updates.

The Countdown Begins

Don't miss this extraordinary opportunity. Register today.

Days

Hours

Minutes

Seconds

Discover what’s top of mind for real-world researchers

Understand how AI is impacting real-world research

Connect with colleagues

Keynote Speaker

Siddhartha Mukherjee

Oncologist and Cancer Researcher, Pulitzer Prize-winning Science Writer

Siddhartha Mukherjee, MD, D.Phil. is a physician, researcher, and author, who serves as Associate Professor of Medicine at Columbia University and as an oncologist at the university’s medical center. Dr. Mukherjee trilogy of books has made a vast contribution to the public discourse on human health, medicine, and science.

The Emperor of All Maladies: A Biography of Cancer earned the 2011 Pulitzer Prize for General Nonfiction, and The Gene: An Intimate History won international awards and was recognized by The Washington Post and The New York Times as one of the most influential books of 2016. Both books have been adapted into PBS documentaries by the renowned filmmaker Ken Burns. The Emperor of All Maladies was included among Time magazine’s 100 best nonfiction books of the past century.

As a medical scholar, Dr. Mukherjee has conducted innovative research that signals a paradigm shift in cancer pathology and has enabled the development of treatments that disrupt current pharmaceutical models toward new biological and cellular therapies.